PMID: 8596740Dec 1, 1995Paper

Anti-CEA labelling kit BW 431/26. Results of the European multicenter trial

Nuklearmedizin. Nuclear Medicine
A Steinsträsser, E Oberhausen

Abstract

In seven European countries a multicenter trial with the 99mTc-labelled monoclonal anti-CEA antibody BW 431/26 was conducted in 730 patients. The antibody is used for the immunoscintigraphic visualisation of CEA-expressing tumours. Investigated were in particular colorectal tumours, bladder and breast carcinoma, medullary thyroid carcinoma, adenocarcinoma of the lung and gastric carcinoma. The main area of use is the detection of recurrences and screening for foci in patients with rising serum CEA. The sensitivity amounts to at least 80% in case of primary colorectal tumours (n = 129) and their abdominal or pelvic metastases (n = 33) and to 90% for their recurrences (n = 107). HAMAs were detectable in less than 15% of patients investigated for the first time. In 17% of the patients examined, immunoscintigraphy was the only technique to visualize the lesion whereas all other diagnostic methods had failed. The procedure yielded additional information in 24-51% of cases.

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

Related Papers

The Quarterly Journal of Nuclear Medicine : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR)
D FusterF Pons
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
M R VieiraJ M de Almeida
© 2021 Meta ULC. All rights reserved